$
0.000
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation

AXDX Relative Valuation

AXDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXDX is overvalued; if below, it's undervalued.

Historical Valuation

No Data

Competitors Valuation Multiple

The average P/S ratio for AXDX's competitors is 2.17, providing a benchmark for relative valuation. Accelerate Diagnostics Inc Corp (AXDX) exhibits a P/S ratio of 0.27, which is -87.37% above the industry average. Given its robust revenue growth of -6.97%, this premium appears unsustainable.

FAQ

arrow icon

Is Accelerate Diagnostics Inc (AXDX) currently overvalued or undervalued?

Accelerate Diagnostics Inc (AXDX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.27 is considered Undervalued compared with the five-year average of 14.13. The fair price of Accelerate Diagnostics Inc (AXDX) is between 0.35 to 0.58 according to relative valuation methord. Compared to the current price of 0.05 USD , Accelerate Diagnostics Inc is Undervalued By 85.67% .
arrow icon

What is Accelerate Diagnostics Inc (AXDX) fair value?

arrow icon

How does AXDX's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?

arrow icon

What is the current FCF Yield for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?

arrow icon

What is the current Forward P/E ratio for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?

arrow icon

What is the current Forward P/S ratio for Accelerate Diagnostics Inc (AXDX) as of May 20 2025?